Article
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
BMJ open - 2 Jun 2017
Kowalec Kaarina, Kingwell Elaine, Carruthers Robert, Marrie Ruth Ann, Bernatsky Sasha, Traboulsee Anthony, Ross Colin J D, Carleton Bruce, Tremlett Helen
Abstract excerpt
INTRODUCTION: Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.